| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | LAK; 8430410J10Rik |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human ALPK1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CD6抗体的3篇代表性文献及其摘要概括：
1. **文献名称**: *CD6 is a modulator of the immunological synapse in human T cells*
**作者**: Hassan, N.J., et al.
**摘要**: 该研究揭示了CD6在调节T细胞免疫突触形成中的作用，发现CD6与其配体ALCAM的结合影响T细胞受体信号传导，为靶向CD6的免疫治疗提供了理论依据。
2. **文献名称**: *Targeting CD6 for the treatment of autoimmune diseases*
**作者**: Oliveira, M.I., et al.
**摘要**: 通过临床前实验，研究发现抗CD6单抗(如itolizumab)可选择性抑制自身反应性T细胞活化，显著改善银屑病和类风湿性关节炎动物模型的症状，支持其作为自身免疫疾病治疗的潜力。
3. **文献名称**: *Phase I/II study of itolizumab, a novel anti-CD6 monoclonal antibody, in chronic plaque psoriasis*
**作者**: Krupashankar, D.S., et al.
**摘要**: 该临床试验评估了抗CD6单抗itolizumab在中度至重度银屑病患者中的安全性和有效性，结果显示药物耐受性良好，并显著降低疾病活动度，支持其进入后续临床开发。
如需更多文献或具体领域(如结构生物学或肿瘤免疫)，可进一步补充说明。
CD6 is a cell surface glycoprotein predominantly expressed on T cells and a subset of B cells, first identified in the 1980s as a key marker for T-cell development and activation. Structurally, it belongs to the scavenger receptor cysteine-rich (SRCR) superfamily and interacts with its ligand CD166 (ALCAM), which is expressed on antigen-presenting cells (APCs) and epithelial cells. This interaction facilitates immunological synapse formation, enhancing T-cell activation, adhesion, and migration. CD6 has been implicated in modulating both pro-inflammatory and regulatory immune responses, making it a therapeutic target for autoimmune diseases and cancers.
Research on CD6-targeting antibodies gained momentum due to their potential to disrupt pathological T-cell activation while preserving immune surveillance. Early studies revealed that anti-CD6 antibodies could dampen T-cell proliferation and cytokine production in vitro, suggesting utility in conditions like rheumatoid arthritis, multiple sclerosis, and psoriasis. Notably, Itolizumab, a humanized anti-CD6 monoclonal antibody, has shown efficacy in Phase III trials for chronic plaque psoriasis and has been explored in COVID-19-related cytokine storms. Its mechanism involves partial CD6 receptor modulation rather than complete blockade, reducing systemic immunosuppression risks.
Despite progress, challenges remain, including understanding CD6's dual roles in immune regulation and optimizing antibody specificity to minimize off-target effects. Ongoing studies aim to clarify its signaling pathways and expand clinical applications, positioning CD6 antibodies as promising biologics in immunotherapy.
×
